159 related articles for article (PubMed ID: 36994823)
1. Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis.
Ran D; Yang B; Sun L; Wang N; Qu P; Liu J; Pan F; Wang G; Wu W; Zhang Z; Shi Z; Yang Q; Liu H; Zhang F
Clin Exp Dermatol; 2023 Jul; 48(7):803-805. PubMed ID: 36994823
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
[TBL] [Abstract][Full Text] [Related]
3. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
Elewski BE; Lebwohl MG; Anadkat MJ; Barker J; Ghoreschi K; Imafuku S; Mrowietz U; Li L; Quaresma M; Thoma C; Bachelez H
J Am Acad Dermatol; 2023 Jul; 89(1):36-44. PubMed ID: 36870370
[TBL] [Abstract][Full Text] [Related]
4. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
Bukhari T; Markovina M; Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
Skin Therapy Lett; 2024 Jan; 29(1):1-4. PubMed ID: 38271532
[TBL] [Abstract][Full Text] [Related]
5. Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
[TBL] [Abstract][Full Text] [Related]
6. Spesolimab: A Novel Treatment for Pustular Psoriasis.
Ratnarajah K; Jfri A; Litvinov IV; Netchiporouk E
J Cutan Med Surg; 2020; 24(2):199-200. PubMed ID: 32208020
[No Abstract] [Full Text] [Related]
7. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.
Maçães CO; Lé AM; Torres T
J Dermatolog Treat; 2022 Nov; 33(7):2911-2918. PubMed ID: 35695278
[TBL] [Abstract][Full Text] [Related]
8. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.
Burden AD
Expert Rev Clin Immunol; 2023 May; 19(5):473-481. PubMed ID: 36960829
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
Burden AD; Okubo Y; Zheng M; Thaçi D; van de Kerkhof P; Hu N; Quaresma M; Thoma C; Choon SE
Exp Dermatol; 2023 Aug; 32(8):1279-1283. PubMed ID: 37140190
[TBL] [Abstract][Full Text] [Related]
10. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
[TBL] [Abstract][Full Text] [Related]
11. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
[TBL] [Abstract][Full Text] [Related]
12. Spesolimab: First Approval.
Blair HA
Drugs; 2022 Nov; 82(17):1681-1686. PubMed ID: 36418672
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: A 48-week retrospective study.
Ruan SF; Zhang LL; Liu Z; Lin TT; Wang HQ; Xu QY; Xiang N; Cheng B; Liu T; Ha HY; Gong T; Ji C
J Am Acad Dermatol; 2023 Jan; 88(1):243-246. PubMed ID: 35588923
[No Abstract] [Full Text] [Related]
14. Two cases of generalized pustular psoriasis successfully treated with bimekizumab.
Hagino T; Saeki H; Kanda N
J Dermatol; 2023 Oct; 50(10):e357-e358. PubMed ID: 37334759
[No Abstract] [Full Text] [Related]
15. Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis.
Ito M; Kamata M; Uchida H; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Tada Y
Br J Dermatol; 2022 Nov; 187(5):793-795. PubMed ID: 35661135
[No Abstract] [Full Text] [Related]
16. Successful treatment with secukinumab in a patient with generalized pustular psoriasis preceded by palmoplantar lesions.
Sawai N; Kawakami Y; Tachibana K; Nomura H; Miyake T; Yokoyama E; Hirai Y; Morizane S
J Dermatol; 2023 Dec; 50(12):e413-e414. PubMed ID: 37577828
[No Abstract] [Full Text] [Related]
17. Spesolimab for the treatment of generalized pustular psoriasis: real life experience.
Dattola A; Taliano A; Rallo A; Pellacani G; Richetta AG
Ital J Dermatol Venerol; 2024 Feb; 159(1):61-62. PubMed ID: 38226936
[No Abstract] [Full Text] [Related]
18. Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient.
Megna M; Abategiovanni L; Annunziata A; Torta G; Peduto T; Fabbrocini G; Lauro W
Dermatol Ther; 2022 May; 35(5):e15382. PubMed ID: 35170168
[No Abstract] [Full Text] [Related]
19. Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab.
Akaji K; Nakagawa Y; Kakuda K; Takafuji M; Kiyohara E; Murase C; Takeichi T; Akiyama M; Fujimoto M
J Dermatol; 2021 Jan; 48(1):e43-e44. PubMed ID: 33063316
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
